The Molecular Basis and Therapeutic Potential of Leukemia Inhibitory Factor in Cancer Cachexia.
Ruijiang ZengChang TongXiangyang XiongPublished in: Cancers (2022)
Cachexia is a chronic metabolic syndrome that is characterized by sustained weight and muscle mass loss and anorexia. Cachexia can be secondary to a variety of diseases and affects the prognosis of patients significantly. The increase in inflammatory cytokines in plasma is deeply related to the occurrence of cachexia. As a member of the IL-6 cytokine family, leukemia inhibitory factor (LIF) exerts multiple biological functions. LIF is over-expressed in the cancer cells and stromal cells of various tumors, promoting the malignant development of tumors via the autocrine and paracrine systems. Intriguingly, increasing studies have confirmed that LIF contributes to the progression of cachexia, especially in patients with metastatic tumors. This review combines all of the evidence to summarize the mechanism of LIF-induced cachexia from the following four aspects: (i) LIF and cancer-associated cachexia, (ii) LIF and alterations of adipose tissue in cachexia, (iii) LIF and anorexia nervosa in cachexia, and (iv) LIF and muscle atrophy in cachexia. Considering the complex mechanisms in cachexia, we also focus on the interactions between LIF and other key cytokines in cachexia and existing therapeutics targeting LIF.
Keyphrases
- metabolic syndrome
- adipose tissue
- end stage renal disease
- bone marrow
- squamous cell carcinoma
- chronic kidney disease
- ejection fraction
- physical activity
- cardiovascular disease
- skeletal muscle
- drug delivery
- risk assessment
- insulin resistance
- oxidative stress
- prognostic factors
- young adults
- cancer therapy
- drug induced
- high glucose